Aspen To Buy Sigma's Generic Drug Business

Pending shareholder approval and the completion of due diligence, Aspen Pharmaceutical Holdings will acquire Sigma Pharmaceuticals' generic drug for AUD900mn (US$811mn) in cash. The purchase price is considerably above the initial AUD707mn (US$637mn) offer in May 2010 and the subsequent scaled-back bid of AUD648mn (US$584mn), which was tabled following a review of Sigma's troubled financial accounts.

To read the full article, please choose one of the following options: